论文部分内容阅读
通过制剂学手段延长头孢氨苄的释放,制成一日服2次代替原需分4次服用的口服制剂,以提高病人的顺应性和临床治疗效果。用微生物法测定头孢氨苄缓缓释胶囊在10例健康志愿者体内的药物动力学和生物利用度,并与进口复粒胶囊和普通胶囊进行了比较研究。生物利用度结果表明,缓释胶囊的有关药动学参数与进口复粒胶囊相比,均无显著性差异(P>0.05),与普通胶囊相比,T_(max)和T_(1/2)有显著的差异(P<0.05),而C_(max)和AUC均无显著性差异。缓释胶囊对进口复粒胶囊的相对生物利用度为98.70％,对普通胶囊为97.28％。
Cefalexin extended by the formulation of the release of cephalexin, made one day to take the place of oral 2 times instead of taking 4 times to improve the patient’s compliance and clinical treatment. The pharmacokinetics and bioavailability of cefalexin sustained-release capsules in 10 healthy volunteers were determined by the microbiological method and compared with the imported capsules and ordinary capsules. The results of bioavailability showed that the pharmacokinetic parameters of sustained release capsules were not significantly different from those of imported capsules (P> 0.05). Compared with ordinary capsules, the values of T max and T 1/2 ) (P <0.05), but there was no significant difference between Cmax (max) and AUC. The relative bioavailability of sustained-release capsules to imported multi-grain capsules was 98.70% and that of common capsules was 97.28%.